Recursion Pharmaceuticals

Industrializing drug discovery by decoding biology at massive scale using machine learning and automation.

Recursion combines high-throughput cellular imaging, advanced ML, and automation to systematically map biology and chemistry. Their platform has generated over 50 petabytes of proprietary biological and chemical data, enabling rapid identification of novel drug candidates across therapeutic areas from oncology to rare diseases. In November 2024 Recursion acquired AI drug-discovery company Exscientia in an all-stock transaction and has integrated its operations.

Headquarters
Salt Lake City, United States
Founded
2013
Compliance
SOC 2 Type II, ISO 27001
Deployment options
cloud
Website
https://www.recursion.com
LinkedIn
https://www.linkedin.com/company/4990022

Categories

AI Use Cases

  • Target Identification & Validation

Vendor Scorecard

100% — Complete coverage. Coverage score — how completely Atlas documents Recursion Pharmaceuticals across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.

Compliance & Validation — Documented

SOC 2 Type II, ISO 27001

Deployment & Hosting — Documented

cloud

Pricing Transparency — Documented

Partnership / milestone based

Implementation & Onboarding — Documented

12+ months

Organization & Role Fit — Documented

Large Pharma, Top 20 Pharma, Drug Discovery, R&D Leadership

Solution Scope — Documented

Biomarker Discovery, Target Identification

Company Viability — Documented

Public, $672M raised, 600+ employees, Founded 2013

Always ask the vendor

Not captured in Atlas data — confirm directly. Excluded from the score above.

Data Rights & IP

Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?

Model Credibility & Explainability

Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?

Clinical Trial Activity

9 registered trials where Recursion Pharmaceuticals is the lead sponsor (5 currently recruiting). Source: ClinicalTrials.gov, verified 2026-07-29.

Phases: Phase 1 (2), Phase 2 (3), Phase 1/Phase 2 (3), Phase 2/Phase 3 (1)

Top conditions studied: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Solid Tumor, APC Gene Mutation, AXIN1 Gene Mutation

Evidence & Outcomes

U.S. FDA Fast Track designation for REC-2282 in NF2-mutated meningiomas

The U.S. FDA granted Fast Track designation to REC-2282, Recursion's orally bioavailable, CNS-penetrant HDAC inhibitor for NF2-mutated meningiomas. Fast Track is intended to expedite the review of investigational drugs that treat serious conditions and address an unmet medical need.

press release (Recursion (PR Newswire)) · 2021-10-07

Roche and Genentech collaboration with $150M upfront payment

Recursion entered a multi-year collaboration with Roche and Genentech to discover novel targets in neuroscience and an oncology indication, receiving a $150 million upfront payment with potential for substantial milestone payments.

press release (Recursion (Investor Relations)) · 2021-12-07 — Partner: Roche / Genentech

Merger with Exscientia completed to form combined AI drug-discovery company

Recursion completed its all-stock merger with Exscientia, combining Recursion's data-generation and ML platform with Exscientia's generative design and automated synthesis capabilities into a single end-to-end AI drug-discovery company.

news (Pharmaceutical Technology) · 2024-11-20 — Partner: Exscientia

Questions to Ask This Vendor

  • How does Recursion handle data exclusivity and IP on discovered compounds?
  • What is the minimum dataset size for a custom phenomics model?
  • How do you ensure reproducibility across imaging batches?